These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. AR-induced ZEB1-AS1 represents poor prognosis in cholangiocarcinoma and facilitates tumor stemness, proliferation and invasion through mediating miR-133b/HOXB8. Jiang X; Li J; Wang W; Hu Z; Guan C; Zhao Y; Li W; Cui Y Aging (Albany NY); 2020 Jan; 12(2):1237-1255. PubMed ID: 31978895 [TBL] [Abstract][Full Text] [Related]
4. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs. Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317 [No Abstract] [Full Text] [Related]
5. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. Cadamuro M; Brivio S; Mertens J; Vismara M; Moncsek A; Milani C; Fingas C; Cristina Malerba M; Nardo G; Dall'Olmo L; Milani E; Mariotti V; Stecca T; Massani M; Spirli C; Fiorotto R; Indraccolo S; Strazzabosco M; Fabris L J Hepatol; 2019 Apr; 70(4):700-709. PubMed ID: 30553841 [TBL] [Abstract][Full Text] [Related]
8. Long non‑coding RNA ZEB1‑AS1 predicts a poor prognosis and promotes cancer progression through the miR‑200a/ZEB1 signaling pathway in intrahepatic cholangiocarcinoma. Jiao M; Ning S; Chen J; Chen L; Jiao M; Cui Z; Guo L; Mu W; Yang H Int J Oncol; 2020 Jun; 56(6):1455-1467. PubMed ID: 32236578 [TBL] [Abstract][Full Text] [Related]
9. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Cadamuro M; Nardo G; Indraccolo S; Dall'olmo L; Sambado L; Moserle L; Franceschet I; Colledan M; Massani M; Stecca T; Bassi N; Morton S; Spirli C; Fiorotto R; Fabris L; Strazzabosco M Hepatology; 2013 Sep; 58(3):1042-53. PubMed ID: 23505219 [TBL] [Abstract][Full Text] [Related]
10. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Clapéron A; Mergey M; Aoudjehane L; Ho-Bouldoires TH; Wendum D; Prignon A; Merabtene F; Firrincieli D; Desbois-Mouthon C; Scatton O; Conti F; Housset C; Fouassier L Hepatology; 2013 Dec; 58(6):2001-11. PubMed ID: 23787814 [TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions. Massani M; Stecca T; Fabris L; Caratozzolo E; Ruffolo C; Furlanetto A; Morton S; Cadamuro M; Strazzabosco M; Bassi N Oncol Rep; 2013 Sep; 30(3):1143-8. PubMed ID: 23807641 [TBL] [Abstract][Full Text] [Related]
12. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma. Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918 [No Abstract] [Full Text] [Related]
13. Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. Gentilini A; Lori G; Caligiuri A; Raggi C; Di Maira G; Pastore M; Piombanti B; Lottini T; Arcangeli A; Madiai S; Navari N; Banales JM; Di Matteo S; Alvaro D; Duwe L; Andersen JB; Tubita A; Tusa I; Di Tommaso L; Campani C; Rovida E; Marra F Hepatology; 2021 Oct; 74(4):2007-2020. PubMed ID: 33959996 [TBL] [Abstract][Full Text] [Related]
14. Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment. Shi A; Liu Z; Fan Z; Li K; Liu X; Tang Y; Hu J; Li X; Shu L; Zhao L; Huang L; Zhang Z; Lv G; Zhang Z; Xu Y Gut; 2024 Jul; 73(8):1350-1363. PubMed ID: 38458750 [TBL] [Abstract][Full Text] [Related]
15. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870 [TBL] [Abstract][Full Text] [Related]
16. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Yang H; Lu X; Liu Z; Chen L; Xu Y; Wang Y; Wei G; Chen Y Oncotarget; 2015 Mar; 6(8):6310-25. PubMed ID: 25749036 [TBL] [Abstract][Full Text] [Related]
17. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells. Thongchot S; Ferraresi A; Vidoni C; Loilome W; Yongvanit P; Namwat N; Isidoro C Cancer Lett; 2018 Aug; 430():160-171. PubMed ID: 29802929 [TBL] [Abstract][Full Text] [Related]
18. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. Raggi C; Taddei ML; Sacco E; Navari N; Correnti M; Piombanti B; Pastore M; Campani C; Pranzini E; Iorio J; Lori G; Lottini T; Peano C; Cibella J; Lewinska M; Andersen JB; di Tommaso L; Viganò L; Di Maira G; Madiai S; Ramazzotti M; Orlandi I; Arcangeli A; Chiarugi P; Marra F J Hepatol; 2021 Jun; 74(6):1373-1385. PubMed ID: 33484774 [TBL] [Abstract][Full Text] [Related]
19. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. Heits N; Heinze T; Bernsmeier A; Kerber J; Hauser C; Becker T; Kalthoff H; Egberts JH; Braun F BMC Cancer; 2016 May; 16():322. PubMed ID: 27206490 [TBL] [Abstract][Full Text] [Related]